Newsletters
oncology
- 2024-10-04 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approvals & Key Cancer Trials
- 2024-10-03 - 🧬 [nGram] Today’s Oncology Scoop: UGN-103 Trial, Gilead's HIV Initiative, Enara Bio Funding
- 2024-10-02 - 🧬 [nGram] Today’s Oncology Scoop: ENHERTU® Priority Review, Owkin & AstraZeneca AI Partnership, Volastra FDA Fast Track
- 2024-10-01 - 🧬 [nGram] Today’s Oncology Scoop: ENHERTU® Priority Review, Merus Phase 3 Trial, Perjeta® Biosimilar Success
- 2024-09-30 - 🧬 [nGram] Today’s Oncology Scoop: Genentech Acquires Regor's CDK Inhibitors, Enliven's Positive Phase 1 Data, Estrella's Complete Response
- 2024-09-27 - 🧬 [nGram] Today’s Oncology Scoop: TAGRISSO® Approval, Tempus & Takeda Collaboration, BeiGene FDA Update
- 2024-09-26 - 🧬 [nGram] Today’s Oncology Scoop: Merck’s KEYTRUDA® New Approvals, Bayer’s Darolutamide Application, BioAge Labs IPO
- 2024-09-25 - 🧬 [nGram] Today’s Oncology Scoop: Takeda's FRUZAQLA Approval, Junshi's Toripalimab in EU, Silexion's Phase 2 Data
- 2024-09-24 - 🧬 [nGram] Today’s Oncology Scoop: Takeda's FRUZAQLA Approval, Datopotamab Deruxtecan Results, PADCEV & KEYTRUDA Approval
- 2024-09-23 - 🧬 [nGram] Today’s Oncology Scoop: BioCity's BC3195 at ESMO, Merck's KEYTRUDA, IDEAYA's Darovasertib
- 2024-09-20 - 🧬 [nGram] Today’s Oncology Scoop: Neu-REFIX Beta Glucan, Narmafotinib, Edgewise Therapeutics, Tolebrutinib
- 2024-09-19 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approves Merck’s KEYTRUDA, ESMO 2024 Highlights, Brenus Pharma Raises $25M
- 2024-09-18 - 🧬 [nGram] Today’s Oncology Scoop: Merck’s KEYTRUDA® Approval, ImCheck’s Fast Track, Brenus Pharma Funding
- 2024-09-17 - 🧬 [nGram] Today’s Oncology Scoop: ESMO 2024 Highlights, FDA Guidance, and Breakthrough Trials
- 2024-09-16 - 🧬 [nGram] Today’s Oncology Scoop: RYBREVANT® & KEYTRUDA® Show Promising Results
- 2024-09-13 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approves Roche’s Tecentriq Hybreza, Marengo & Gilead Collaboration, Bicara IPO
- 2024-09-12 - 🧬 [nGram] Today’s Oncology Scoop: Sanofi's Radioligand Deal, Aura's Phase 2 Success, PIONeeR at ESMO
- 2024-09-11 - 🧬 [nGram] Today’s Oncology Scoop: Pfizer at ESMO, Viridian & REVEAL Genomics Results
- 2024-09-10 - 🧬 [nGram] Today’s Oncology Scoop: OSE Immunotherapeutics Launches Phase 3 Study, Innovent's Phase 2 Results, ORYZON's Phase Ib Study
- 2024-09-09 - 🧬 [nGram] Today’s Oncology Scoop: Ivonescimab vs Pembrolizumab, Novocure's TTFields, Natera's Signatera™
- 2024-09-06 - 🧬 [nGram] Today’s Oncology Scoop: Abdera's FDA Orphan Drug, Akeso & Gilead at ESMO 2024
- 2024-09-05 - 🧬 [nGram] Today’s Oncology Scoop: ALX Oncology Doses First Patients, Merck's New Trials, Synthekine's FDA Fast Track
- 2024-09-04 - 🧬 [nGram] Today’s Oncology Scoop: Merck at ESMO, Pancreatic Cancer Trial, Cogent Biosciences Phase 3
- 2024-09-03 - 🧬 [nGram] Today’s Oncology Scoop: Merck’s KEYTRUDA® Approval, HighField’s IND Filing, Simcere Zaiming Collaboration
- 2024-08-30 - 🧬 [nGram] Today’s Oncology Scoop: Bayer's NSCLC Trial, Noetik's $40M Series A, and More
- 2024-08-29 - 🧬 [nGram] Today’s Oncology Scoop: Merck Trials, CancerVax Nanotech, Innovent at WCLC & ESMO
- 2024-08-28 - 🧬 [nGram] Today’s Oncology Scoop: FDA Priority Review for SpringWorks, EC Approves Astellas' PADCEV, Telix Submits NDA
- 2024-08-27 - 🧬 [nGram] Today’s Oncology Scoop: LIXTE’s LB-100 Trial, RYBREVANT® Approval, RedHill's Orphan Drug
- 2024-08-26 - 🧬 [nGram] Today’s Oncology Scoop: Galapagos FDA Clearance, GI Innovation & KEYTRUDA, Opna Bio Doses First Patient
- 2024-08-21 - 🧬 [nGram] Today’s Oncology Scoop: Exact Sciences MCED Study, BerGenBio & Tempus Collaboration, Inocras-Broad Institute Agreement
- 2024-08-20 - 🧬 [nGram] Today’s Oncology Scoop: RYBREVANT® & LAZCLUZE™ Approval, MOMA-313 Phase 1, ENHERTU® EMA Validation
- 2024-08-19 - 🧬 [nGram] Today’s Oncology Scoop: PT217 Orphan Drug Designation, MMRF CoMMpass Study
- 2024-08-16 - 🧬 [nGram] Today’s Oncology Scoop: Nuntius & Taiho mRNA Collaboration, New Hope for Neuroblastoma, Esopredict Study Results
- 2024-08-15 - 🧬 [nGram] Today’s Oncology Scoop: IMFINZI® Priority Review, Niktimvo™ FDA Approval, Positive Clinical Updates
- 2024-08-14 - 🧬 [nGram] Today’s Oncology Scoop: PanTher's FDA Clearance, Viracta's Positive Data, Financial Updates
- 2024-08-13 - 🧬 [nGram] Today’s Oncology Scoop: Biosyngen's FDA Approval, Junshi's New Drug Application, Citius Merger
- 2024-08-12 - 🧬 [nGram] Today’s Oncology Scoop: Halda Therapeutics Secures $126M, Kiromic BioPharma Trial Update
- 2024-08-09 - 🧬 [nGram] Today’s Oncology Scoop: Merck Acquires CN201, Abzena Supplies AGX101, Q2 Financial Results
- 2024-08-08 - 🧬 [nGram] Today’s Oncology Scoop: Merck's KeyVibe-008, Citius FDA Approval, WestGene's Dual INDs
- 2024-08-07 - 🧬 [nGram] Today’s Oncology Scoop: Exelixis FDA Update, Daiichi Sankyo & Merck Deal, IDRx Financing
- 2024-08-06 - 🧬 [nGram] Today’s Oncology Scoop: Elevation, Lantern, SEED, Galvanize & More
- 2024-08-05 - 🧬 [nGram] Today’s Oncology Scoop: Adaptimmune's FDA Approval, Gene Therapy for Synovial Sarcoma, Galapagos Trial Pause
- 2024-08-02 - 🧬 [nGram] Today’s Oncology Scoop: Adaptimmune's TECELRA® FDA Approval, Jemperli Expanded Use, New Trials & More
- 2024-08-01 - 🧬 [nGram] Today’s Oncology Scoop: ALX Oncology's Phase 2 Success, Immuneering's FDA Fast Track, OS Therapies IPO
- 2024-07-31 - 🧬 [nGram] Today’s Oncology Scoop: IMUNON's Ovarian Cancer Breakthrough, Umoja's FDA Clearance, DARZALEX FASPRO® Approval
- 2024-07-30 - 🧬 [nGram] Today’s Oncology Scoop: BioNTech's Phase 2 Success, IMUNON's Upcoming Results, Verastem's FDA Orphan Drug Status
- 2024-07-29 - 🧬 [nGram] Today’s Oncology Scoop: CHMP Recommends RYBREVANT®, CStone's Sugemalimab Approved, Immorta Bio's SenoVax™ IND
- 2024-07-26 - 🧬 [nGram] Today’s Oncology Scoop: FDA Grants Orphan Drug Status to Cellectis’ UCART22, Summit & MD Anderson Collaboration, Presage Biosciences Doses First Patient
- 2024-07-25 - 🧬 [nGram] Today’s Oncology Scoop: Inimmune Doses First Patient, Novartis Collaboration, Notable Labs FDA Clearance
- 2024-07-24 - 🧬 [nGram] Today’s Oncology Scoop: AffyImmune RMAT, BioAtla Fast Track, Anixa IND
- 2024-07-23 - 🧬 [nGram] Today’s Oncology Scoop: Immutep's FDA Success, BeiGene's New Facility, and More
- 2024-07-22 - 🧬 [nGram] Today’s Oncology Scoop: Nuvalent Doses First Patient, Zymeworks FDA Clearance, TME Pharma Strategy
- 2024-07-19 - 🧬 [nGram] Today’s Oncology Scoop: Bristol Myers Squibb's Opdivo, AVEO's Phase 3 Results, Deciphera's EMA Application
- 2024-07-18 - 🧬 [nGram] Today’s Oncology Scoop: Junshi's New Drug Application & Biotheryx's Phase 1 Trial
- 2024-07-17 - 🧬 [nGram] Today’s Oncology Scoop: Bayer's NUBEQA® Phase III Success, FDA Orphan Drug Designations
- 2024-07-16 - 🧬 [nGram] Today’s Oncology Scoop: Biosyngen's BRG01 Phase II, Mabwell's NMPA Approval, GRAIL's Galleri® Trial
- 2024-07-12 - 🧬 [nGram] Today’s Oncology Scoop: Senhwa IND, Revolution Medicines, KOLON Phase III
- 2024-07-11 - 🧬 [nGram] Today’s Oncology Scoop: Rgenta's IND Clearance, Kazia's Phase II/III Results, Can-Fite's Orphan Drug Application
- 2024-07-10 - 🧬 [nGram] Today’s Oncology Scoop: Obsidian's FDA Fast Track, Curium's NDA, Prelude & Merck Collaboration
- 2024-07-09 - 🧬 [nGram] Today’s Oncology Scoop: SELLAS Orphan Drug, iOnctura NSCLC Trial, Radionetics-Lilly Deal
- 2024-07-08 - 🧬 [nGram] Today’s Oncology Scoop: Immorna, IDEAYA, Hinova, Biostar, iTeos, Myricx, XPOVIO, Olverembatinib, IASO
- 2024-07-05 - 🧬 [nGram] Today’s Oncology Scoop: Breakthrough in Breast Cancer Treatment, New Drug Approval, and More
- 2024-07-04 - 🧬 [nGram] Today’s Oncology Scoop: Roche's SKYSCRAPER-06 Update, Boehringer's SIRP Treatment, HUTCHMED's NDA
- 2024-07-03 - 🧬 [nGram] Today’s Oncology Scoop: Legend Biotech's CARTITUDE-4, Biogen's Acquisition, Full-Life's FDA Fast Track
- 2024-07-02 - 🧬 [nGram] Today’s Oncology Scoop: Allogene's Phase 2 Trial, Ipsen's Cabometyx Expansion, Orion & MSD's Opevesostat Deal
- 2024-07-01 - 🧬 [nGram] Today’s Oncology Scoop: BALVERSA® & RYBREVANT® Get EU Nod, SCG Cell Therapy FDA IND Clearance
- 2024-06-28 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approvals, New Data, and Clinical Trial Updates
- 2024-06-27 - 🧬 [nGram] Today’s Oncology Scoop: EPKINLY® FDA Approval, GenVivo Trial, Cancer Drug Shortage
- 2024-06-26 - 🧬 [nGram] Today’s Oncology Scoop: Lyell's CAR-T, Simcere's Cetuximab, Junshi's Toripalimab
- 2024-06-25 - 🧬 [nGram] Today’s Oncology Scoop: IMFINZI® Success, Oncoinvent Fast Track, Merck KGaA Update
- 2024-06-24 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approvals, Clinical Updates & More
- 2024-06-21 - 🧬 [nGram] Today’s Oncology Scoop: Allogene's Phase 2 Trial, Oncolytics' New Study, Tempest's Survival Data
- 2024-06-20 - 🧬 [nGram] Today’s Oncology Scoop: Basilea Partners with Glioblastoma Foundation, iOnctura Secures EUR80M
- 2024-06-19 - 🧬 [nGram] Today’s Oncology Scoop: GenFleet's IND Approval, Golidocitinib's New Approval, Medivir's Phase 2b Study, Aethlon's Ethics Approval
- 2024-06-18 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approves Merck’s KEYTRUDA, Junshi's sNDA for Toripalimab, Evaxion's 67% Response Rate
- 2024-06-17 - 🧬 [nGram] Today’s Oncology Scoop: IMFINZI® Approval, Roche’s Columvi Success, BLINCYTO® FDA Nod
- 2024-06-14 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approves Augtyro™, ASCO 2024 Highlights, and More
- 2024-06-13 - 🧬 [nGram] Today’s Oncology Scoop: MSK's Pancreatic Cancer Breakthrough, Innovent's FDA Fast Track, Immorta Bio's Lung Cancer Success
- 2024-06-12 - 🧬 [nGram] Today’s Oncology Scoop: City of Hope CAR T Cell Therapy, Junshi Biosciences Phase 3 Success, OBI Pharma's New Study
- 2024-06-11 - 🧬 [nGram] Today’s Oncology Scoop: FDA Clears Lomonitinib, SL-172154 Orphan Drug, Ultimovacs Phase I Update
- 2024-06-10 - 🧬 [nGram] Today’s Oncology Scoop: Roche’s Alecensa Approved, TAGRISSO® Priority Review, Zymeworks in China
- 2024-06-07 - 🧬 [nGram] Today’s Oncology Scoop: FDA Approves Geron's RYTELO™, AbbVie's Positive Phase 2 Results, and More
- 2024-06-06 - 🧬 [nGram] Today’s Oncology Scoop: BridgeBio Doses First Patient, AbbVie Starts Ph. 3 Trial, Replimune Positive Data
- 2024-06-05 - 🧬 [nGram] Today’s Oncology Scoop: Bristol Myers Squibb's Opdivo/Yervoy Success, Pierre Fabre's IND Filing, MAIA's THIO Efficacy
neurology
- 2024-10-04 - 🧬 [nGram] Today’s Neurology Scoop: CALQUENCE® Priority Review, Opdivo® Approval, Reproxalap Resubmission
- 2024-10-03 - 🧬 [nGram] Today’s Neurology Scoop: Charles River & Lundbeck AI Drug Discovery, SetPoint MS Study
- 2024-10-02 - 🧬 [nGram] Today’s Neurology Scoop: BPGbio's Huntington’s & Alzheimer’s Breakthroughs, Maze's CKD Trial, Papillon's Orphan Drug
- 2024-10-01 - 🧬 [nGram] Today’s Neurology Scoop: Santhera's LIONHEART Results, CLINUVEL's SCENESSE® Submission, KalVista's Sebetralstat Applications
- 2024-09-30 - 🧬 [nGram] Today’s Neurology Scoop: KarXT & COBENFY FDA Approvals, BlueRock's Parkinson's Data
- 2024-09-27 - 🧬 [nGram] Today’s Neurology Scoop: FDA Approves New Schizophrenia Drug, KarXT Approval, Phase 3 DEEp SEA Study
- 2024-09-26 - 🧬 [nGram] Today’s Neurology Scoop: FDA Approvals, IPOs, and Key Trials
- 2024-09-25 - 🧬 [nGram] Today’s Neurology Scoop: FDA Approves New Drug, Novartis AI Collaboration, Spine BioPharma Phase 3
- 2024-09-24 - 🧬 [nGram] Today’s Neurology Scoop: Lilly's Kisunla™ Approved in Japan, Amneal Launches CREXONT®
- 2024-09-23 - 🧬 [nGram] Today’s Neurology Scoop: Biohaven's Troriluzole, FDA Niemann-Pick Approval, Teva's Schizophrenia Data
- 2024-09-20 - 🧬 [nGram] Today’s Neurology Scoop: Tolebrutinib's MS Breakthrough, Neu-REFIX FDA Designations, and More!
- 2024-09-19 - 🧬 [nGram] Today’s Neurology Scoop: FDA Approves Merck’s KEYTRUDA, argenx in The Lancet, Anokion's MS Data
- 2024-09-18 - 🧬 [nGram] Today’s Neurology Scoop: Charles River & CEBINA Collab, ImCheck FDA Fast Track, Oxford Brain & Memory Treatment
- 2024-09-17 - 🧬 [nGram] Today’s Neurology Scoop: ESMO 2024 Highlights, FDA Guidance, and Key Clinical Trials
- 2024-09-16 - 🧬 [nGram] Today’s Neurology Scoop: FDA Approves OCREVUS ZUNOVO™ for MS
- 2024-09-13 - 🧬 [nGram] Today’s Neurology Scoop: FDA Grants RPD to Senhwa's Silmitasertib for Pediatric Neuroblastoma
- 2024-09-12 - 🧬 [nGram] Today’s Neurology Scoop: Fulcrum, Aura, Seres, ProMIS, Bright Minds & More
- 2024-09-11 - 🧬 [nGram] Today’s Neurology Scoop: Viridian, Stoke, T-Neuro, Incendia, Delta-Fly, Basking, Inflammasome, Nxera, Kallyope, REVEAL GENOMICS
- 2024-09-10 - 🧬 [nGram] Today’s Neurology Scoop: Innovent's Dupert® Results, Datopotamab Deruxtecan's Survival Data, ImmunityBio's Positive Data
- 2024-09-09 - 🧬 [nGram] Today’s Neurology Scoop: FDA Supports αSyn-SAA, Novocure at ESMO, MBX IPO
- 2024-09-06 - 🧬 [nGram] Today’s Neurology Scoop: Abdera's FDA Orphan Drug, Ocuphire's Phase 3 Trial, LUCA's Groundbreaking Research
- 2024-09-05 - 🧬 [nGram] Today’s Neurology Scoop: Synthekine's FDA Fast Track, Vaxcyte's $1.3B Offering, Adaptin Bio's IND Clearance
- 2024-09-04 - 🧬 [nGram] Today’s Neurology Scoop: Roche’s MS Breakthrough, FDA Orphan Drug for ALS, Glioblastoma Therapy
- 2024-08-30 - 🧬 [nGram] Today’s Neurology Scoop: Merck's Phase III Study & Kiyatec's 3D Predict™ Glioma
- 2024-08-29 - 🧬 [nGram] Today’s Neurology Scoop: Merck Updates, Repare's Focus, Azitra's Phase 1b, Vaxart's HPV Vaccine
- 2024-08-28 - 🧬 [nGram] Today’s Neurology Scoop: FDA Priority for SpringWorks, Ocugen Dosing, Neurocrine Positive Data
- 2024-08-27 - 🧬 [nGram] Today’s Neurology Scoop: Ocugen's Phase 3 Trial, Invivyd's COVID-19 Breakthrough, RedHill's Orphan Drug
- 2024-08-26 - 🧬 [nGram] Today’s Neurology Scoop: UK Approves Leqembi, NHS Access Denied
- 2024-08-21 - 🧬 [nGram] Today’s Neurology Scoop: SPARK NS Awards $10M for Parkinson’s Research
- 2024-08-20 - 🧬 [nGram] Today’s Neurology Scoop: Alzamend Neuro's Phase II Trial, SciSparc's Enrollment, Alpha Cognition's Patent
- 2024-08-19 - 🧬 [nGram] Today’s Neurology Scoop: Clearmind & Yissum's New Psychedelic Patent
- 2024-08-16 - 🧬 [nGram] Today’s Neurology Scoop: Quince's Phase 3 ATTeST Data & uniQure's Fabry Disease Trial
- 2024-08-15 - 🧬 [nGram] Today’s Neurology Scoop: Vaccinex SIGNAL-AD Trial Update & Quince Therapeutics' Lancet Publication
- 2024-08-14 - 🧬 [nGram] Today’s Neurology Scoop: Cybin's FDA Meeting, Leqembi in UAE, Rejoyn™ Launch
- 2024-08-13 - 🧬 [nGram] Today’s Neurology Scoop: Alzamend Neuro's Phase II Trial, Amylyx's Alzheimer’s Data, Neuronetics-Greenbrook Merger
- 2024-08-12 - 🧬 [nGram] Today’s Neurology Scoop: NurExone's ExoPTEN, n-Lorem in Nature Medicine, Neurotech Patent
- 2024-08-09 - 🧬 [nGram] Today’s Neurology Scoop: Parkinson's Trial, Orphan Drug Designation, AI-Generated Candidate
- 2024-08-08 - 🧬 [nGram] Today’s Neurology Scoop: Neurogene's RMAT for Rett, Amneal's FDA Approval, ANEW's Patents
- 2024-08-07 - 🧬 [nGram] Today’s Neurology Scoop: Clene's ALS Data, Sangamo & Genentech Deal, Indapta's MS Trial
- 2024-08-06 - 🧬 [nGram] Today’s Neurology Scoop: Alzamend Neuro's Phase II Trial, Telitacicept Enrollment, ProMIS Data on ALS
Charts
- Trend of Total Assets in U.S. Pharmaceuticals and Medicines Corporations from 2000 to 2023
- Top 10 Quarters with Highest Total Assets in U.S. Pharmaceuticals and Medicines Corporations
- Trend of Clinical Trials Enrollment Over Time
- Top 5 Most Common Biospecimen Retention Types in Clinical Trials
- Trend of Number of Groups in Clinical Trials Over Time
- Distribution of Clinical Trials by Phase
- Distribution of Clinical Trials by Overall Status
- Trend of Number of Arms in Clinical Trials Over Time
- Trend of Clinical Trials Completion Over Time
- Top 5 Most Common Reasons for Stopping Clinical Trials
- Trend of Clinical Trials Start Dates Over Time
- Distribution of Clinical Trials by Study Type
- Number of clinical trials by year
- Clinical Trials - Terminated, Industry chart
- Number of clinical trials by year
- Clinical Trials chart - ES Cloud
- Total Discontinued and Marketed Drugs
- Discontinued and Marketed drugs
- Discontinued drugs
- Top 10 Sponsors with the Most Studies
- Total Discontinued drugs
- Dev - Targets and MoAs of discontinued and non-marketed drugs
- Distribution of Study Phases
- Trends in Study Completion Over Time
- Count of Oncology Trials Starting in the Next 3 Months
- Comparison of Clinical Trials in Canada vs United States Over the Years
- Trend in Clinical Trials Initiated in the US vs EU in the Last Three Years
- HbA1c Improvement Observed with BASAGLAR in Type 2 Diabetes Patients
- Trend in Clinical Trials Initiated in the US Over the Last Three Years
- Trend of Clinical Trials Over the Last 10 Years
- Trend in Clinical Trials Initiated in Singapore Over the Last Three Years
- Top Pharmaceutical Companies by Number of Trials Published in the Last 5 Years
- Total Enrollment in Phase I, II, and III for the Year 2024
- Trend in Number of Phase III Trials Initiated from 2021 to 2023
- Number of Employees for Top 10 Healthcare Companies
- Enrollment trend in studies over the years
- Number of Employees for Top 10 Healthcare Companies
- companies by market cap
- Top 10 Companies by Market Capitalization within Each Sector
- Top 10 Companies by Market Capitalization in Each Sector
- Top 10 Companies by Market Capitalization in Each Sector
- Top 10 Companies by Market Capitalization in Each Sector
- Top 10 Companies by Market Capitalization in Each Sector
- Top 10 Companies by Market Capitalization in Each Sector
- Number of Employees for Top 10 Healthcare Companies
- 5 Year Trend in Average Market Capitalization for AbbVie
- Number of Employees for Top 10 Healthcare Companies
- Number of Employees for Top 10 Pharma Companies
- Gross Profit Margin Trend for Amgen
- 5 Year Trend in Market Capitalization for AbbVie
- Average Market Capitalization of Abbvie Annually
- Number of Employees for Top 10 Pharmaceutical Companies
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- 5 Year Trend in Average Market Capitalization for AbbVie
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
- 5 Year Trend in Average Market Capitalization for AbbVie
- Average Debt-to-Equity Ratio Over the Years for Gilead
- Market Capitalization Comparison of NovoNordisk and Eli Lilly Over the Last 5 Years
- Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
- Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
- Number of Employees for Top 10 Healthcare Companies
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Annual Trend of Median Household Income in the U.S.
- Top 10 companies with highest market capitalization in 2024
- Average Cost of Revenue Comparison Among Selected Companies
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- 5 Year Trend in Average Market Capitalization for Abbvie
- Average Debt-to-Equity Ratio Over the Years for Gilead
- EBITDA Trend for Merck & Co. from 2019 to 2023
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Average Debt-to-Equity Ratio Over the Years for Gilead
- Annual trend of average enterprise value across all companies
- Yearly trend of total debt across all companies
- Annual trend of average stock price across all companies
- Number of Employees for Top 10 Pharma Industry Companies
- Top 5 companies with highest enterprise value in 2024
- Top 10 Recent Clinical Trials by Completion Date
- Quarterly Revenue Trend for Publicly Traded Companies
- Comparison of Cost of Revenue Among Selected Companies
- Quarterly Gross Profit Trend for Publicly Traded Companies
- Quarterly Revenue Trend for Publicly Traded Companies
- Quarterly General and Administrative Expenses for Publicly Traded Companies
- Quarterly Research and Development Expenses for Publicly Traded Companies
- Number of Employees for Top 10 Pharma Sector Companies
- Number of Employees for Top 10 Healthcare Companies
- Comparison of R&D Expense between Pfizer and AstraZeneca in 2023
- Quarterly Cost of Revenue Trend for Publicly Traded Companies
- Gross Profit Margin Trend for Amgen
- Number of Employees for Each of the Top 10 Pharma Companies
- Number of Employees for Top 10 Pharma Companies
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Number of Employees for Top 10 Pharma Companies
- Number of Clinical Trials Started in the Last 5 Years
- Number of Employees for Top 10 Healthcare Companies
- Number of Employees for Top 10 Healthcare Companies
- Number of Employees for Each of the Top 10 Pharma Companies
- 5 Year Trend in Average Market Capitalization for AbbVie
- 5 Year Trend in Average Market Capitalization for AbbVie
- 5 Year Trend in Average Market Capitalization for Abbvie
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Comparison of R&D Expenses between Pfizer and AstraZeneca in 2023
- Number of Employees for Top 10 Healthcare Companies
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Number of Employees for Top 10 Pharma Companies
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Market Capitalization Comparison of NovoNordisk and Eli Lilly Over the Last 5 Years
- Number of Employees for Top 10 Healthcare Companies
- Last 5 Year Trend in Market Capitalization for AbbVie
- Top 10 Recent Clinical Trials by Completion Date
- Number of Employees for Top 10 Healthcare Companies
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Comparison of R&D Expense for Pfizer and AstraZeneca in 2023
- Comparison of Average Cost of Revenue Among Selected Companies
- 5 Year Trend in Average Market Capitalization for AbbVie
- Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithkline
- Number of Employees for Top 10 Pharma Industry Companies
- 5 Year Trend in Average Market Capitalization for AbbVie
- 5 Year Trend in Average Market Capitalization for Abbvie
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, Eli Lilly Over the Last 8 Quarters
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Market Capitalization Comparison of NovoNordisk and Eli Lilly Over the Last 5 Years
- Net Income Margin Comparison for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Last 5 Year Trend in Market Capitalization for AbbVie
- Last 5 Year Trend in Market Capitalization for AbbVie
- Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
- 5 Year Trend in Average Market Capitalization for Abbvie
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Number of Employees for Top 10 Pharma Industry Companies
- Market Capitalization Comparison for NovoNordisk and Eli Lilly Over the Last 5 Years
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- 5 Year Trend in Average Market Capitalization for Abbvie
- Net Income Margin Comparison for Glaxosmithkline, AstraZeneca, Takeda, Eli Lilly Over the Last 8 Quarters
- 5 Year Trend in Average Market Capitalization for Abbvie
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- 5 Year Trend in Market Capitalization for AbbVie
- Number of Clinical Trials Conducted in the Last 5 Years by Top 10 Pharma Industry Companies
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Gross Profit Margin Trend for Amgen
- Comparison of Cost of Revenue Among Selected Companies
- Number of Employees for Top 10 Pharma Companies
- Comparison of Cost of Revenue Among Selected Companies
- Market Capitalization Comparison for NovoNordisk and Eli Lilly Over the Last 5 Years
- Number of Employees for Each of the Top 10 Pharma Companies
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Gross Profit Margin Trend for Amgen
- Number of Employees for Top 10 Pharma Companies
- Net Income Margin Comparison for Glaxosmithkline, AstraZeneca, Takeda, Eli Lilly Over the Last 8 Quarters
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Comparison of Cost of Revenue for Selected Companies Over Years
- Last 5 Year Trend in Market Capitalization for AbbVie
- Market Capitalization Comparison for NovoNordisk and Eli Lilly Over the Last 5 Years
- Number of Employees for Each of the Top 10 Pharma Companies
- Last 5 Year Trend in Market Capitalization for AbbVie
- Gross Profit Margin Trend for Amgen
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Comparison of Cost of Revenue Among Selected Companies
- Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline
- Gross Profit Margin Trend for Amgen
- Number of Employees for Each of the Top 10 Pharma Companies
- Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline
- Comparison of Cost of Revenue Among Selected Companies
- Market Capitalization Comparison for NovoNordisk and Eli Lilly Over the Last 5 Years
- Number of Employees for Each of the Top 10 Pharma Companies
- Market Capitalization Comparison of NovoNordisk and Eli Lilly Over the Last 5 Years
- Market Overview and Future Predictions for Ozempic
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Last 5 Year Trend in Market Capitalization for AbbVie
- Comparison of Cost of Revenue for Selected Companies Over Years
- Gross Profit Margin Trend for Amgen
- Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Comparison of Cost of Revenue for Selected Companies Over Years
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Annual SG&A Expense Ratio Comparison for AstraZeneca, Pfizer, and GlaxoSmithKline
- ABBV Balance Sheet Metrics for Q1 2024
- Last 5 Year Trend in Market Capitalization for AbbVie
- Top 10 Biopharma Companies by Revenue in Q2 2024
- Comparison of Market Capitalization for NovoNordisk and Eli Lilly Over the Last 5 Years
- Net Income Margin Comparison for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters
- Number of Employees for Each of the Top 10 Healthcare Companies
- Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
- Number of Employees for Top 10 Healthcare Companies
- Market Capitalization Comparison for NovoNordisk and Eli Lilly Over the Last 5 Years